During the last session, 9 Meters Biopharma Inc. (NASDAQ:NMTR)’s traded shares were 3.2 million, with the beta value of the company hitting -2.28. At the end of the trading day, the stock’s price was $0.24, reflecting an intraday loss of -3.36% or -$0.01. The 52-week high for the NMTR share is $1.46, that puts it down -508.33 from that peak though still a striking 16.67% gain since the share price plummeted to a 52-week low of $0.20. The company’s market capitalization is $64.02M, and the average intraday trading volume over the past 10 days was 2.55 million shares, and the average trade volume was 4.14 million shares over the past three months.
9 Meters Biopharma Inc. (NMTR) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.70. NMTR has a Sell rating from 0 analyst(s) out of 6 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 5 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.04.
9 Meters Biopharma Inc. (NASDAQ:NMTR) trade information
9 Meters Biopharma Inc. (NMTR) registered a -3.36% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -3.36% in intraday trading to $0.24 this Wednesday, 08/03/22, hitting a weekly high. The stock’s 5-day price performance is 7.38%, and it has moved by 13.06% in 30 days. Based on these gigs, the overall price performance for the year is -77.42%. The short interest in 9 Meters Biopharma Inc. (NASDAQ:NMTR) is 5.14 million shares and it means that shorts have 0.6 day(s) to cover.
The consensus price target of analysts on Wall Street is $2.80, which implies an increase of 91.43% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $1.00 and $4.00 respectively. As a result, NMTR is trading at a discount of -1566.67% off the target high and -316.67% off the low.
9 Meters Biopharma Inc. (NMTR) estimates and forecasts
Statistics show that 9 Meters Biopharma Inc. has underperformed its competitors in share price, compared to the industry in which it operates. 9 Meters Biopharma Inc. (NMTR) shares have gone down -67.84% during the last six months, with a year-to-date growth rate less than the industry average at -13.33% against 1.00. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to shrink -33.30% this quarter and then jump 20.00% in the quarter after that.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 57.80%. While earnings are projected to return 74.00% in 2022.
9 Meters Biopharma Inc. is due to release its next quarterly earnings on November 15. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
9 Meters Biopharma Inc. (NASDAQ:NMTR)’s Major holders
9 Meters Biopharma Inc. insiders own 4.01% of total outstanding shares while institutional holders control 27.63%, with the float percentage being 28.78%. Adage Capital Partners GP L.L.C. is the largest shareholder of the company, while 122 institutions own stock in it. As of Mar 30, 2022, the company held over 15.0 million shares (or 5.79% of all shares), a total value of $8.99 million in shares.
The next largest institutional holding, with 13.99 million shares, is of Blackrock Inc.’s that is approximately 5.40% of outstanding shares. At the market price on Mar 30, 2022, these shares were valued at $8.38 million.
Also, the Mutual Funds coming in first place with the largest holdings of 9 Meters Biopharma Inc. (NMTR) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. Data provided on Mar 30, 2022 indicates that Vanguard Total Stock Market Index Fund owns about 6.73 million shares. This amounts to just over 2.60 percent of the company’s overall shares, with a $4.03 million market value. The same data shows that the other fund manager holds slightly less at 3.04 million, or about 1.17% of the stock, which is worth about $1.82 million.